FDA-approved1,2Evidence: Smaller human trialsMetabolic and weight

Dasiglucagon1

Also called Zegalogue1,2

Key takeaway

Dasiglucagon is a lab-made 29-amino-acid analogue of glucagon, the hormone that raises blood sugar. It is the active ingredient in Zegalogue, which FDA approved in 2021 for severe low blood sugar in people with diabetes aged 6 and older.1,2 In three randomized, placebo-controlled trials described in the label, blood sugar recovered faster with dasiglucagon than with placebo; in the largest, of 170 adults, the median time was 10 minutes versus 40.1 Drugs@FDA now lists both Zegalogue products as discontinued.2

Dasiglucagon at a glance

What it isA synthetic glucagon analogue of 29 amino acids that activates glucagon receptors in the liver, according to the Zegalogue label.1
FDA statusFDA-approved, but discontinued. Drugs@FDA lists Zegalogue, NDA 214231, with an original approval date of March 22, 2021, and lists both of its products as discontinued.2
Human evidenceThree randomized, double-blind, placebo-controlled trials in people with type 1 diabetes, two in adults and one in children aged 6 to 17, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is dasiglucagon?

Dasiglucagon is a synthetic analogue of the hormone glucagon, made of 29 amino acids, according to the label.1

In the United States it is the active ingredient of Zegalogue, approved under NDA 214231, according to Drugs@FDA.2

How does dasiglucagon work?

The label states that dasiglucagon activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood. It needs liver glycogen stores to work.1

What do human studies show?

The label describes three randomized, double-blind, placebo-controlled trials in people with type 1 diabetes whose blood sugar was lowered under controlled conditions. The main outcome was the time for blood sugar to recover.1

In Trial A, 170 adults were randomized to dasiglucagon, placebo or glucagon. Median recovery took 10 minutes with dasiglucagon, 40 minutes with placebo and 12 minutes with glucagon, according to the label.1

What the evidence base contains

  • Controlled human trial Trial A (NCT03378635): a randomized, double-blind trial in 170 adults with type 1 diabetes comparing dasiglucagon with placebo and with glucagon after induced low blood sugar, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is dasiglucagon FDA-approved?

Yes, but Drugs@FDA lists both Zegalogue products under application NDA 214231 as discontinued. The application’s original approval date is March 22, 2021.2

The Zegalogue label cited here (DailyMed SPL version 3, published June 17, 2026) states that it is indicated for severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.1

The label has no boxed warning. It states that dasiglucagon must not be used in people with pheochromocytoma, because it may trigger a large rise in blood pressure, and warns that it can cause later low blood sugar in people with insulinoma.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list dasiglucagon.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Dasiglucagon is not among them.4,5

Timeline

  1. FDA approves Zegalogue, NDA 214231, according to Drugs@FDA.2
  2. DailyMed publishes the Zegalogue label version cited on this page.1

What is still unknown?

How it performs in real emergencies: the trials described in the label lowered blood sugar under controlled conditions and had no formal statistical comparison with glucagon.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Dasiglucagon: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Dasiglucagon are a bounded selection, not every registration or paper about Dasiglucagon. For the years before Dasiglucagon was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Dasiglucagon as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Dasiglucagon in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Zegalogue for severe low blood sugar; discontinued. Three randomized, placebo-controlled trials described in the label found faster blood sugar recovery with dasiglucagon than with placebo. Dasiglucagon is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Dasiglucagon?

FDA-approved as Zegalogue for severe low blood sugar; discontinued. Three randomized, placebo-controlled trials described in the label found faster blood sugar recovery with dasiglucagon than with placebo. Dasiglucagon is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
8
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Dasiglucagon?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

20Selected dated records
25Connected citations
8Populated source years2017–2026
3/4Record lanes present

Registered human studies

Trial composition

16 of 16 selected trial records include at least one phase value; 16 of 16 include a status value in the retained structured contract.

PhasesPhase 3 10Phase 2 7Phase 1 1
Status at observationCompleted 16

PubMed bibliography

Publication composition

2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1Letter 1Research Support, N.I.H., Extramural 1Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
20

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 20 dated records

Research hub

Explore the Dasiglucagon evidence record

Open all 20 records →
20Dated records
3Evidence types
20Cited public sources
8Source years

Change ledger

Recently changed for Dasiglucagon

Open all 20 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT02916251

PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
April 21, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03216226

PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
May 4, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03378635

PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
June 10, 2021
Evidence lane
Clinical trials

Official-source collections

Source records for Dasiglucagon

Open the full research atlas →
PubMed2

2 with attributed title, venue, publication-date, and type metadata.

  1. Dasiglucagon Hydrochloride.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021 Jul 22
  2. Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.Diabetes care · 2021 04 27
Explore all selected literature →
ClinicalTrials.gov16

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03941236Registry update August 3, 2026 · completed at observation
  2. NCT05378672Registry update July 20, 2025 · completed at observation
  3. NCT04172441Registry update March 14, 2025 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span April 21, 2017 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 20

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.↗

    PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Dasiglucagon Hydrochloride.↗

    PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03941236↗

    PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05378672↗

    PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04172441↗

    PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03777176↗

    PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  7. Regulatory

    Federal Register notice 2023-26260↗

    The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03895697↗

    PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT04836273↗

    PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT04764968↗

    PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT03667053↗

    PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT03378635↗

    PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026